Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P03951
UPID:
FA11_HUMAN
Alternative names:
Plasma thromboplastin antecedent
Alternative UPACC:
P03951; D3DP64; Q4W5C2; Q9Y495
Background:
Coagulation factor XI, also known as Plasma thromboplastin antecedent, plays a pivotal role in the intrinsic pathway of blood coagulation by activating factor IX. This protein is essential for proper blood clot formation, ensuring that bleeding is effectively controlled following injury.
Therapeutic significance:
Factor XI deficiency, a hemorrhagic disease, is directly linked to mutations affecting this protein, leading to reduced levels and activity. This condition results in moderate bleeding symptoms, particularly after trauma or surgery, highlighting the protein's critical role in hemostasis and its potential as a target for therapeutic intervention.